OnCo
ideasIdea

Inhaled immune therapy to make the lung hostile to arriving tumour cells

Breathing in an immune-activating drug could turn the lungs into bad soil for cancer seeds, at doses far too low to cause body-wide side-effects.

Inhaled GM-CSF was tested in paediatric osteosarcoma lung metastases and inhaled interleukin-2 in renal cancer, both with local immune activation, acceptable safety and underpowered efficacy. Modern versions — an inhaled interleukin-15 superagonist, an inhaled STING agonist or an inhaled anti-CD47 — could be aimed at lung-metastasis prevention rather than treatment, where the target cell burden is tiny.

Hypothesis
Inhaled alveolar immune activation after resection of a lung-tropic tumour halves lung-specific relapse without systemic cytokine toxicity.
Rationale
Metastasis prevention needs high local and low systemic exposure, and the lung is the only metastatic site with a direct non-invasive delivery route. Alveolar macrophage reprogramming is the mechanistic target and is measurable by bronchoalveolar lavage.
What would test it
A phase 1/2 in resected osteosarcoma or lung-tropic sarcoma with lavage-based pharmacodynamics, then a randomised trial with lung-relapse-free survival as the primary endpoint.
Maturity
preclinical evidence
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
6
Bottlenecks it attacks

Connected

8top

Pages like this

not linked directly; found by shared links